Laruen Gutierrez
Family · Wilmington, DENPI 1285030627
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 219 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,124, 2.1 times the $534 reported in 2021. Among family clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 219 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$515
- AstraZeneca$484
- Bayer$429
- GSK$359
- Merck$260
- Novo Nordisk$248
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,069100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 32 | $515 |
| AstraZeneca | 20 | $484 |
| Bayer | 24 | $429 |
| GSK | 20 | $359 |
| Merck | 16 | $260 |
| Novo Nordisk | 15 | $248 |
| Boehringer Ingelheim | 12 | $198 |
| Exact Sciences | 10 | $194 |
| AbbVie | 9 | $162 |
| Astellas Pharma US Inc | 6 | $114 |
| Pfizer | 5 | $100 |
| Esperion Therapeutics, Inc. | 5 | $99 |
| Sanofi-aventis U.S. LLC | 4 | $79 |
| Amgen | 5 | $77 |
| Lundbeck LLC | 3 | $77 |
| Biohaven Pharmaceuticals, Inc. | 2 | $72 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| Insulet Corporation | 2 | $63 |
| Xeris Pharmaceuticals, Inc. | 3 | $61 |
| Dexcom, Inc. | 2 | $48 |
| Hologic Sales And Service, LLC | 2 | $47 |
| Kowa Pharmaceuticals America, Inc. | 3 | $46 |
| Novartis | 2 | $31 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Shield Therapeutics Inc | 2 | $30 |
| Bausch Health US, LLC | 1 | $29 |
| Corcept Therapeutics | 1 | $25 |
| Abbott | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Verona Pharma, Inc. | 1 | $16 |
| Tolmar, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$4,069 in reported general payments places this provider in the 90th percentile of 523 family providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 44 | $63,353 |
| OzempicSemaglutide | 44 | $53,272 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $37,897 |
| EliquisApixaban | 21 | $26,792 |
| TradjentaLinagliptin | 22 | $20,765 |
| XareltoRivaroxaban | 14 | $14,116 |
| MounjaroTirzepatide | 12 | $12,794 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 37 | $11,555 |
| TrulicityDulaglutide | 11 | $10,528 |
| Atorvastatin Calcium | 357 | $5,133 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 23 | $5,042 |
| Levothyroxine Sodium | 114 | $2,204 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 74 | $2,016 |
| Amlodipine Besylate | 224 | $1,871 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,837 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $198 | $84,11866 claims |
| Novo NordiskOzempic | $248 | $53,27244 claims |
| GSKTrelegy Ellipta, Shingrix | $359 | $42,93974 claims |
| PfizerEliquis, Abrysvo | $100 | $38,34758 claims |
| Lilly USA, LLCMounjaro, Trulicity | $515 | $23,32223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 523 family providers in Delaware.
Other family in Wilmington
- Tracy EstesWilmington$59K
- Jodi KahanWilmington$21K
- Elizabeth Sharp-AsiyoWilmington$13K
- Shannon HogateWilmington$10K
- Carolyn BarrettWilmington$10K
- Gloria DiazWilmington$8K
- Amy HitchensWilmington$8K
- Emmanuel AntonioWilmington$7K
- Stephanie Evans MitchellWilmington$6K
- Sidonie SalmonWilmington$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.